Genotype and antiretroviral drug resistance of human immunodeficiency virus-1 in Saudi Arabia

Saudi Medical Journal

Volumn 31, Issue 9, 2010, Pages 987-992

  Jamjoom, Ghazi A ^a   Azhar, Esam I ^a   Madani, Tariq A ^b   Hindawi, Salwa I ^a   Bakhsh, Hanaa A ^c   Damanhouri, Ghazi A ^a  

^a Kingdom of Saudi Arabia   (Saudi Arabia)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c King Abdulaziz University   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZODOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG SENSITIVITY; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; SAUDI ARABIA;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; GENES, POL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SAUDI ARABIA; TREATMENT FAILURE;

EID: 77958472721     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350: 1023-1035.
2. Clotet B, Menendez-Arias L, Schapiro JM, Kuritzkes D, Burger D, Telenti A, et al, editors. Guide to management of HIV drug resistance, antiretrovirals pharmacokinetics and viral hepatitis in HIV infected subjects. 8th ed. Catalonia (Spain): Fundacio de Lluita contra la SIDA; 2008.
3. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21: 215-223.
4. Hirsch MS, Günthard H F, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47: 266-285.
5. Haubrich R, Demeter L. International perspectives on antiretroviral resistance. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. J Acquir Immune Defc Syndr 2001; 26: Suppl 1: S51-S59.
6. Yerly S, Vora S, Rizzardi P, Chave J P, Vernazza PL, Flepp M, et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15: 2287-2292.
7. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001; 322: 1087-1088.
8. Descamps D, Chaix ML, Andre P, Brodard V, Cottalorda J, Deveau C, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defc Syndr 2005; 38: 545-552.
9. Yerly S, Von Wyl V, Ledergerber B, Boni J, Schupbach J, Burgisser P, et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 2007; 21: 2223-2229.
10. Little SJ, Holte S, Routy J P, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
11. Richman DD, Morton S, Wrin T, Hellmann N, Berry S, Shapiro M F, Bozzette SA. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18: 1393-1401.
12. Hofmann C, Rockstroh JK, Kamps BS, editors. HIV resistance testing. HIV Medicine. 15th ed. Paris (France); Flying Publishers: 2007. p. 321-351.
13. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. Available at http://www. aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
14. Working Group on Antiretroviral Terapy and Medical Management of HIV-infected Children. Guidelines for the use of antiretroviral agents in Pediatric HIV Infection February 23, 2009; pp 1-139. Available from URL: http://www.aidsinfo.nih. gov/ContentFiles/PediatricsGuidlines.pdf
15. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. May 24, 2010; pp 1-117. Available from URL: http://www.aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf
16. Madani TA, Al-Mazrou YY, Al-Jefri MH, Al Huzaim NS. Epidemiology of the human immunodefciency virus in Saudi Arabia; 18-year surveillance results and prevention from an Islamic perspective. BMC Infect Dis 2004; 4: 25.
17. Esparza J, Bhamarapravati N. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? Lancet 2000; 355: 2061-2066.
18. Xiao-Jie L, Uenishi R, Hase S, Liao H, Keng TK, Kusagawa S, et al. HIV/AIDS in Asia: Te Shape of Epidemics and Their Molecular Epidemiology. Virologica Sinica 2007; 22: 426-433.
19. Martinez-Cajas JL, Pai N P, Klein MB, Wainberg MA. Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc 2009; 12: 11.
20. Schendure J, Hanlee JI. Next-generation DNA sequencing. Nature Biotechnology 2008; 26: 1135-1145.